Sartorius Stedim Biotech S.A.
SDMHF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 5.50 | -3.33 | 0.61 | 1.24 |
| FCF Yield | -0.45% | 0.25% | 0.30% | 1.12% |
| EV / EBITDA | 85.64 | 109.09 | 80.31 | 154.61 |
| Quality | ||||
| ROIC | 1.45% | 1.27% | 1.41% | 1.48% |
| Gross Margin | 46.39% | 46.27% | 47.85% | 42.10% |
| Cash Conversion Ratio | 0.94 | 1.35 | 1.04 | 6.97 |
| Growth | ||||
| Revenue 3-Year CAGR | 1.23% | -2.97% | -5.22% | -7.33% |
| Free Cash Flow Growth | -278.41% | -10.09% | -73.40% | 8.93% |
| Safety | ||||
| Net Debt / EBITDA | 10.40 | 11.27 | 8.69 | 16.51 |
| Interest Coverage | 2.72 | 4.17 | 2.23 | 9.79 |
| Efficiency | ||||
| Inventory Turnover | 0.52 | 0.58 | 0.57 | 0.64 |
| Cash Conversion Cycle | 136.94 | 109.88 | 117.22 | 109.53 |